March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
1 citations
,
July 2025 in “PubMed” Cord blood platelet-rich plasma may safely improve vulvar lichen sclerosus symptoms.
March 2026 in “Science China Materials” SeV-Tp speeds up healing of drug-resistant infections by targeting wounds and killing bacteria with light activation.
July 2016 in “Cancer Research” A topical lotion helped manage hair loss from chemotherapy by affecting cell death, inflammation, and collagen, with no side effects.
2 citations
,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
25 citations
,
January 2005 in “Pediatric Dermatology” Methotrexate effectively treated a 2-year-old's generalized pustular psoriasis without side effects.
March 2014 in “Journal of The American Academy of Dermatology” A botanical extract may help manage hair loss from chemotherapy by preventing cell death in hair follicles.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
April 2007 in “The Journal of Urology” Finasteride reduces bleeding risk during prostate surgery.
December 2014 in “Journal of Biomedical Research” Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
1 citations
,
August 2018 in “Journal of The American Academy of Dermatology” Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
March 2005 in “European Urology Supplements” January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
19 citations
,
April 2016 in “Case Reports in Dermatology” Nilotinib can cause keratosis pilaris, a skin condition.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.